Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus

Title: Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus
Edition: Original
Classification: Standard guideline
Field: Diagnosis and Treatment
Countries and regions: China
Guidelines users: Dermatologists and rheumatologists all over the world, who provide clinical care for patients with lupus erythematosus.
Evidence classification method: Due to the limited clinical evidence available for most of therapeutic measures applied for CLE, all participants in the guideline committee agreed to develop this guideline based on both expert consensus and evidence. Voting results for each recommendation were calculated. Recommendations passing a 90% agreement or above in votes were regarded as strong consensus, and recommendations with a 70-89% agreement in votes were regarded as consensus. All recommendations in this guideline passed with a >80% agreement.
Development unit: 亚洲皮肤科学会,亚洲皮肤病学与性病学会,中华医学会皮肤性病学分会红斑狼疮研究中心
Registration time: 2021-07-09
Registration number: IPGRP-2021CN189
Purpose of the guideline: Cutaneous lupus erythematosus (CLE) is an inflammatory, autoimmune disease encompassing a broad spectrum of subtypes including acute, subacute, chronic and intermittent CLE. Among these, chronic CLE can be further classified into several subclasses of lupus erythematosus (LE) such as discoid LE, verrucous LE, LE profundus, chilblain LE and Blaschko linear LE. To provide all dermatologists and rheumatologists with a practical guideline for the diagnosis, treatment and long-term management of CLE, this evidence- and consensus-based guideline was developed following the checklist established by the international Reporting Items for Practice Guidelines in Healthcare (RIGHT) Working Group.